AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease
Primary analysis is a success and confirms interim analysis
Company to host webcast on masitinib in ALS
AB Science SA...
als
clinical
cure
data
death
disability
drugs
financial
free
lead
medicine
neurologist
paralysis
progression
research
riluzole
symptoms
test
tests
treatment
trial
tyrosine
update
urgent
website
PARIS, April 4, 2016 --
AB Science Announces Positive Interim Results from Phase 3 Trial of Masitinib in Amyotrophic Lateral Sclerosis (ALS) (also known as Lou Gehrig's disease)
Company to Host Webcast on Masitinib in ALS in the Coming Days
AB Science SA (NYSE Euronext - FR0010557264 - AB), a...
als
atrophy
brain
clinical
clinical study
data
death
disability
fda
fvc
lou gehrig's disease
media
medical
medicine
milestone
muscles
neurology
paralysis
progression
research
respiratory
riluzole
sensitivity
symptoms
treatment
trial
tyrosine